Analysis identifies reduced abuse potential of DORAs in real-world use, suggesting reclassification may be warranted.
This study identified significantly fewer reported cases of real-world abuse, misuse, overdose, and other safety risks for DORAs compared with the unscheduled drug trazodone and scheduled Z-drugs. This suggests that categorization of DORAs as Schedule IV drugs may overstate their abuse potential.
No takes yet. Share an insight, caveat, or question.
Saskin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: